FDA Approves HeartMate II for DT; Expect Near-Term Volatility

Posted on January 21st, 2010

Thoratec’s lead device, the HeartMate II, receives FDA approval for Destination Therapy.

2010 01-21 THOR FDA HMII Approval

About Anthem Equity Group

Anthem is an open-integrated company where our investors, lenders, vendors and team members are part of a seamless organization, committed to working together to maximize our returns in a climate of opportunity and uncertainty. Today’s modern communication tools form the platform for this strategy.